Mumbai, Nov. 14 -- However, revenue from operations increased 20.52% YoY to Rs 2,370 crore during the quarter, supported by broad-based growth across its business segments.

Profit before tax (PBT) tumbled 67.58% to Rs 61.7 crore in Q2 FY27 compared with Rs 190.3 crore in Q2 FY26.

EBITDA fell 27% YoY to Rs 255 crore, compared with Rs 351 crore in the year-ago quarter. Consequently, EBITDA margin contracted by 708 basis points to 10.7% from 17.8%.

Radiopharmacy revenue grew 10% YoY to Rs 667 crore in Q2 FY27, supported by higher volumes of certain PET products. The company's proposed investment of over US$ 60 million towards establishing six new PET manufacturing facilities is progressing, with the sites expected to become operational in...